Table 1.

Diagnosis, age, and sex of patients

Parameter	Overall patients (n = 1771)	MDS (n = 1139)	MPN (n = 125)	Plasma cell neoplasm (n = 23)	Acquired BMF (n = 395)	Congenital BMF (n = 89)
Classification, N (%)		MDS-IB2, 345 (30%) MDS-IB1, 262 (23%) MDS-LB, 407 (36%) MDS-LB-RS, 32 (3%) MDS/MPN, 37 (3%) 5q– syndrome, 5 (0.4%) RAEB-t, 25 (2%) RAEB, 20 (2%) Missing, 6 (0.5%)	CMML, 81 (65%) JMML, 42 (34%) PMF, 1 (0.8%) aCML, 1 (0.8%)	MM, 16 (70%) PCL, 5 (22%) Others, 2 (9%)	IAA, 346 (88%) HAAA, 22 (6%) PRCA, 10 (3%) PNH, 7 (2%) Others, 11 (3%)	FA, 33 (37%) CN, 20 (22%) DBA, 16 (18%) DC, 7 (8%) AMT, 4 (4%) Others, 9 (10%)
Age at HCT (IQR), years	46 (20–75)	54 (41–62)	44 (2–61)	54 (44–57)	19 (12–34)	6 (3–10)
Range	0–75	1–75	0–71	31–70	1–72	0–32
Sex, N (%)
Male	1096 (62%)	738 (65%)	87 (70%)	15 (65%)	217 (55%)	39 (44%)
Female Missing	674 (38%) 1 (0.06%)	400 (35%) 1 (0.09%)	38 (30%)	8 (35%)	178 (45%)	50 (56%)
Patients aged > 45 years, N (%)
Male	604 (34%)	525 (46%)	41 (33%)	11 (48%)	27 (7%)	0 (0%)
Female	304 (17%)	247 (22%)	20 (16%)	6 (26%)	31 (8%)	0 (0%)
Patients aged ≤ 45 years, N (%)
Male	492 (28%)	213 (19%)	46 (37%)	4 (17%)	190 (48%)	39 (44%)
Female	371 (21%)	153 (14%)	18 (14%)	2 (9%)	147 (37%)	50 (56%)
Missing	1 (0.06%)	1 (0.09%)

aCML atypical chronic myelogenous leukemia, AMT amegakaryocytic thrombocytopenia, CMML chronic myelomonocytic leukemia, CN Congenital neutropenia, DBA Diamond-Blackfan anemia, DC dyskeratosis congenita, FA Fanconi anemia, HAAA hepatitis-associated aplastic anemia, IAA idiopathic aplastic anemia, IB increased blasts, LB low blasts, JMML juvenile myelomonocytic leukemia, MM multiple myeloma, MPN myeloproliferative neoplasm, PCL plasma cell leukemia, PNH paroxysmal nocturnal hemoglobinuria, PRCA pure red cell aplasia, RAEB refractory anemia with excess blast, RAEB-t refractory anemia with excess blast in transformation, RS ringed sideroblast